Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVANZ Mite
- Development stage
- Unknown
- Lead developer
- ALK Abelló
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
AVANZ Mite (also known as AVANZ Mite mix) is a subcutaneous specific allergen immunotherapy (SCIT) developed by ALK-Abelló for the treatment of house dust mite-induced allergic rhinitis or rhinoconjunctivitis, with or without asthma. The product consists of a biologically standardized allergen extract derived from the house dust mites *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*, adsorbed onto aluminium hydroxide. It is designed with a simplified, short up-dosing phase (typically 5 weekly injections) to reach the maintenance dose, facilitating patient compliance. AVANZ Mite works by inducing immunological tolerance, characterized by significant increases in allergen-specific IgG4 and IgE-blocking factors, which suppress IgE-mediated allergic responses and reduce immediate skin reactivity.
- Brand names
- AVANZ MiteAVANZ Mite mix
- Other names
- AVANZ Dermatophagoides mezclaAVANZ MitesDermatophagoides mix allergen extract
02
Targets
FCER1 (Fc epsilon RI receptor)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on AVANZ Mite.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVANZ Mite.